Oramed Pharmaceuticals Inc. — Director's Dealing 2012

Nov 6, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP.OB)
CIK: 0001176309
Period of Report: 2012-08-22

Reporting Person: Sank Leonard (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-08-22	Common Stock	A	270270	$0.2717	Acquired	2627920	Direct
2012-11-02	Common Stock	A	135135	$0.2717	Acquired	2763055	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-08-22	Warrant (right to buy)	$0.50	A	135135	Acquired	2017-08-22	Common Stock (135135)	Direct
2012-11-02	Warrant (right to buy)	$0.50	A	67568	Acquired	2017-11-02	Common Stock (67568)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	937500	Indirect
Common Stock	1666667	Indirect

Footnotes

F1: Includes 937,500 shares of common stock held by Mr. Sank's wife. Mr. Sank disclaims beneficial ownership of such securities.

F2: Includes 1,666,667 shares of common stock owned by a company wholly owned by a trust of which Mr. Sank is a trustee. Mr. Sank disclaims beneficial ownership of such securities.

F3: The warrant was fully vested on the date of issuance.

F4: The shares and warrants were purchased as "units" at a price per unit of $0.37 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model.